Sensorion has enrolled the final patient in its NOTOXIS Phase 2a trial evaluating SENS-401 for preventing hearing loss caused by cisplatin chemotherapy, with 47 patients randomized across treatment and control groups.
Sensorion's SENS-501 Audiogene trial treated its first patient, showing initial safety and behavioral changes, with cohort completion expected by year-end.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.